Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transparency comments sought

This article was originally published in The Tan Sheet

Executive Summary

FDA seeks comments on how to improve the agency's transparency to regulated firms, based on input received during Transparency Task Force meetings in January with food, drug and medical device industry representatives. Transcripts from those sessions are accessible at 1www.regulations.gov and on the task force's Web site, 2www.fda.gov/Transparency, according to a March 12 release. FDA is particularly interested in comments on how to make improvements in training and education for regulated industry about FDA's regulatory process in general or about specific new requirements; the guidance development process; maintaining open channels of communication with industry routinely and during crises; providing useful and timely answers to industry questions about specific regulatory issues; and communicating with sponsors during review of applications. Comments are due by April 12
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS103902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel